Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its infant formula business acquired from Nestlé [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchases made between February 27, 2023, and November 4, 2025 [1]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Perrigo - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant was plagued by significant underinvestment and operational deficiencies [3]. - Specific claims include the need for substantial capital expenditures beyond initial estimates to address these issues, leading to overstated financial results [3]. Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, resulting in a 50% decline in earnings per share compared to the previous year [4]. - Following this announcement, Perrigo's stock price fell over 15% [4]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, leading to a nearly 10% drop in stock price [5]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing an 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, resulting in a stock price drop of over 25% [7]. Company Background - Perrigo provides over-the-counter health and wellness solutions and has been involved in significant acquisitions to expand its product offerings [2].

Core Viewpoint - A Los Angeles jury awarded $40 million to two women who allege that Johnson & Johnson's talcum powder caused their ovarian cancer, marking a significant development in ongoing litigation against the company [1][2]. Group 1: Legal Developments - The recent verdict is part of a long-standing legal battle regarding claims that talc in Johnson & Johnson's Baby Powder and Shower to Shower body powder is linked to ovarian cancer and mesothelioma [2]. - In October, another California jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, asserting that her cancer was due to asbestos contamination in the baby powder [3]. - The latest jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband, highlighting the plaintiffs' long-term loyalty to the brand [4]. Group 2: Company Response and Strategy - Johnson & Johnson plans to appeal the jury's liability verdict and compensatory damages, asserting that it has won 16 out of 17 ovarian cancer cases previously tried [4]. - The company maintains that the jury's findings contradict decades of independent scientific evaluations that confirm talc is safe, does not contain asbestos, and does not cause cancer [5]. - In response to declining sales, Johnson & Johnson replaced talc in its baby powder with cornstarch in 2020 and faced a setback in April when a U.S. bankruptcy court judge denied its plan to pay $9 billion to settle related litigation claims [5].

Core Thesis - Johnson & Johnson (J&J) is viewed positively due to its diversified business model, strong financials, and consistent dividend growth, making it an attractive investment opportunity [1][4]. Business Overview - J&J operates in three major divisions: pharmaceuticals, medical devices, and consumer health products, with pharmaceuticals being the largest growth driver [2]. - The company’s consumer health brands, such as Tylenol and Band-Aid, provide stability and relevance in everyday life, ensuring recurring demand and resilient cash flows [2]. Financial Performance - J&J's revenues increased from $70 billion in 2015 to nearly $89 billion projected for 2024, with operating income exceeding $61 billion [3]. - The company maintains a conservative payout ratio of around 55–60%, supporting its status as a Dividend King with 62 consecutive years of dividend increases [3]. Investment Metrics - J&J scores above 90 on the MaxDividends framework, indicating strong stability across sales growth, profit growth, net income resilience, payout safety, and low leverage [4]. - The stock has a moderate dividend yield of 2.8% and steady growth of approximately 6%, with valuation metrics suggesting it is slightly undervalued compared to peers [4]. Recent Performance - Since a previous bullish thesis in January 2025, J&J's stock price has appreciated by approximately 40.42%, reflecting strong fundamentals and continued investor confidence [5].

Core Thesis - Kenvue Inc. is undergoing a strategic review to optimize its brand portfolio and enhance operating performance, aiming to unlock shareholder value [2][3][4] Company Overview - Kenvue Inc. operates as a consumer health company across multiple regions including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [2] - As of November 28th, Kenvue's share price was $17.35, with a market capitalization of approximately $30 billion and an enterprise value of around $38 billion [3] Financial Metrics - Kenvue's trailing and forward P/E ratios are 23.13 and 15.77 respectively, with an EV/EBITDA multiple of roughly 11× [1][3] - The company offers a dividend yield of about 4%, providing a solid income component for investors [3] Strategic Initiatives - The strategic review may lead to the sale of underperforming Skin Health & Beauty brands, acquisitions in high-growth OTC health categories, and capital reallocation to higher-margin segments [4] - Analysts estimate that these initiatives could raise Kenvue's margins and overall valuation by 15–25% [4] Investment Case - The combination of a disciplined strategic review, potential divestitures, and a focus on higher-margin segments positions Kenvue to enhance profitability and shareholder returns over time [5] - Kenvue's current valuation and dividend yield, along with strategic initiatives, create an attractive investment case for those seeking operational upside and a clear path to value creation [5]

Core Viewpoint - Kimberly-Clark Corporation (NASDAQ:KMB) is recognized as a strong investment opportunity, particularly following its better-than-expected third quarter earnings and plans to acquire Kenvue, enhancing its consumer health presence [2][3]. Group 1: Company Performance - Kimberly-Clark has recently upgraded its rating to Buy from Hold, with a price target set at $120, indicating a positive outlook despite recent stock lagging [2]. - The company reported better-than-expected earnings for the third quarter, which has contributed to the stronger outlook from analysts [2]. Group 2: Acquisition and Market Position - Kimberly-Clark plans to acquire Kenvue, a company that focuses on consumer health and owns several well-known brands, with the deal expected to be completed in the second half of next year [2][3]. - Both Kimberly-Clark and Kenvue operate in resilient product categories, making KMB an attractive long-term investment option [3]. Group 3: Revenue Generation - The majority of Kimberly-Clark's revenue is generated through direct sales to various channels, including retailers, distributors, and online platforms [4]. - The company serves a diverse global customer base, including supermarkets, big-box stores, drugstores, and institutional buyers across multiple sectors [4].

Core Viewpoint - Perrigo Company is facing a class action lawsuit due to allegations of misleading investors about the value of its infant formula business, which has resulted in significant financial repercussions for the company [1][3]. Summary by Sections Company Overview - Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally [1]. Class Action Details - The class period for the lawsuit is from February 27, 2024, to November 4, 2025 [1]. - The lawsuit was filed by Robbins LLP on behalf of all investors who acquired Perrigo securities during the class period [1]. Allegations Against Perrigo - The complaint alleges that Perrigo failed to disclose several critical issues regarding its infant formula business: 1. Significant underinvestment in maintenance, operational improvements, and repairs [3]. 2. The need for substantial capital and operational expenditures beyond previously stated cost estimates to remediate the business [3]. 3. Significant manufacturing deficiencies in the infant formula facility [3]. 4. Overstated financial results, including earnings and cash flow, due to the above issues [3]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to dynamics in the infant formula industry [4]. - The company is initiating a strategic review of its infant formula business and reassessing a previously announced investment of $240 million, indicating that the business has become "less strategic" [4]. - Following this announcement, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [4].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its infant formula business and financial performance during the specified class period [1][4]. Company Overview - Perrigo provides over-the-counter health and wellness solutions and acquired Nestlé's Gateway infant formula plant and the rights to Nestlé's Good Start® infant formula brand for $170 million in November 2022 [3]. Allegations of the Lawsuit - The lawsuit alleges that Perrigo made false or misleading statements and failed to disclose significant issues, including: - Underinvestment in the acquired infant formula business [4]. - The need for substantial capital and operational expenditures beyond stated estimates for remediation [4]. - Significant manufacturing deficiencies in the infant formula facility [4]. - Overstated financial results, including earnings and cash flow [4]. Financial Disclosures and Impact - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation, along with a 50% decline in earnings per share compared to the previous year, leading to a stock price drop of over 15% [5]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, resulting in a nearly 10% drop in stock price [6]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing a stock price decline of more than 11% [7]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, slashing its fiscal year 2025 outlook, which included a negative sales growth guidance of -2.5% to -3% and a significant cut in expected earnings per share, leading to a stock price drop of over 25% [8].

Core Insights - Cullen Capital Management's "SCCM Value Equity Strategy" reported a gross return of 6.9% for Q3 2025, outperforming the Russell 1000 Value's 5.3% and underperforming the S&P 500's 8.1% during the same period [1] - Year-to-date, the strategy achieved a gross return of 13.0%, compared to Russell 1000 Value's +11.7% and S&P 500's +14.8% [1] Company Analysis: Kenvue Inc. (NYSE:KVUE) - Kenvue Inc. experienced a one-month return of 6.43% but has lost 33.33% of its value over the past 52 weeks, with a market capitalization of $30.82 billion as of November 19, 2025 [2] - The company was sold from the SCCM Value Equity Strategy during Q3 2025 due to challenges such as pressures on US consumer spending, delayed seasonal demand, and competition from challenger brands [3] - Kenvue's stock is currently valued at 19x 2025 EPS, which is considered less compelling compared to its initial portfolio addition in 2023 [3] Market Position - Kenvue Inc. is not among the 30 most popular stocks among hedge funds, although it saw an increase in hedge fund holdings from 52 to 72 in the last quarter [4] - Despite its potential, Kenvue is viewed as less attractive compared to certain AI stocks that are believed to offer greater upside potential and lower downside risk [4]

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its infant formula business acquired from Nestlé [1][3]. Company Overview - Perrigo provides over-the-counter health and wellness solutions and acquired Nestlé's Gateway infant formula plant and the rights to the Good Start® brand for $170 million in November 2022 [2]. Allegations of Misleading Statements - The lawsuit alleges that Perrigo failed to disclose significant underinvestment in the acquired infant formula business, which required substantial capital expenditures beyond initial estimates to address operational deficiencies [3]. - Specific allegations include manufacturing deficiencies and overstated financial results, including earnings and cash flow [3]. Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, leading to a 50% decline in earnings per share compared to the previous year [4]. - Following this announcement, Perrigo's stock price fell over 15% [4]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, resulting in a nearly 10% drop in stock price [5]. - On August 6, 2025, adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing an over 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, leading to a more than 25% drop in stock price [7]. Legal Process - Investors who purchased Perrigo securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [8][9].

Core Insights - ProPhase Labs Inc. will present its third quarter 2025 financial results on November 19, 2025, at 2:00 pm EST via a virtual conference call [1][2] - A press release detailing the financial results will be issued prior to the conference call, and stakeholders and investors are invited to register for the event [2] - ProPhase Labs is a next-generation biotech, genomics, and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic tests [4] Company Overview - ProPhase Labs aims to revolutionize healthcare through bold innovation and actionable insights, with a commitment to executional excellence and smart diversification [4] - The company develops, manufactures, and commercializes health and wellness solutions, including OTC dietary supplements [4] - ProPhase Labs emphasizes the potential for long-term value through its valuable subsidiaries and their synergies [4]